By Phoebe Starr
Acute flares leading to hospitalizations and emergency department visits pose a significant health burden, yet approximately 75% of patients with gout who are considered “controlled” on urate-lowering therapy continued to have flares over a 1-year period, according to a study presented at the 2012 meeting of the American College of Rheumatology.
By Phoebe Starr
Ongoing research using DNA sequencing is being used to examine how the microbiome in the oral cavity and in the gastrointestinal tract affects autoimmune diseases such as rheumatoid arthritis (RA), scientists explained at the 2012 meeting of the American College of Rheumatology.
By Phoebe Starr
Strontium ranelate doses of 1 g daily and 2 g daily slowed the progression of knee osteoarthritis (OA) over a 3-year period in the double-blind placebo-controlled Strontium Ranelate in Knee Osteoarthritis Trial (SEKOIA), investigators reported at the 2012 meeting of the American College of Rheumatology.
By Phoebe Starr
By Phoebe Starr
An automated cell phone system used to monitor patients with early rheumatoid arthritis (RA) is a potential way to extend limited healthcare resources.
Intravenous (IV) golimumab (Simponi) significantly delayed radiographic progression in patients with active moderate-to-severe rheumatoid arthritis (RA) for 1 year compared with placebo.
By Phoebe Starr
The way patients with fibromyalgia experience pain may be a result of abnormal pain signal processing associated with reduced opioid receptor binding, according to a study presented during the 2012 meeting of the American College of Rheumatology.
By Mark Knight
Medication use in patients with systemic juvenile idiopathic arthritis (JIA) is highly variable but is gradually shifting toward the increased use of biologic agents, according to presenters who participated at a symposium on the topic at the 2012 meeting of the American College of Rheumatology (ACR).
The treat-to-target guidelines recommend managing patients with early rheumatoid arthritis (RA) to achieve remission as a treatment goal.
Biomarker Panel an Objective Measure of Disease Activity, Treatment Response in Rheumatoid Arthritis
By Wayne Kuznar
A panel of disease biomarkers can measure changes in disease activity in response to a range of therapies for rheumatoid arthritis (RA), researchers announced at the 2012 meeting of the American College of Rheumatology (ACR).